Molecular techniques that quantify and detect circulating HIV RNA have led to a new understanding of the pathogenesis of HIV disease and a new surrogate marker for use in clinical management. Prior to the ability to quantify virion-associated HIV-RNA in the circulation, measurement of disease burden was by quantitative viral culture, by p24 antigen levels, or indirectly by CD4 T-cell enumeration. However, since most patients had no detectable virus or p24 antigen in the plasma during the period of clinical latency following primary infection when their CD4 T-cell count was essentially normal, the virus was thought to be "silent" or "inactive" during this period. High levels of detectable virus by culture or p24 antigen were known to coincide with the fall in CD4 T-cell count to levels below 200/mm3 and the onset of AIDS-associated symptoms. This perspective changed when the p24 antigen method was modified to break apart the antibodyantigen complexes by acid hydrolysis.' This method, referred to as immune-complex dissociated p24 antigen method (ICD-p24) demonstrated that viral p24 antigen was indeed present at various levels during the period of clinical latency, reflecting active viral replication. With 4 This extraordinarily high rate of viral replication and CD4 T-cell turnover has led to a very different concept of disease pathogenesis. Rather than the paradigm of a long "quiet" latency period in the natural history of a chronic viral infection, it is now evident that the immune system of the HIV-infected individual is waging war daily, even during early and asymptomatic disease.5 It is equally clear that if viral replication and mutation continue to occur at significant rates while on an antiretroviral regimen, strong selection pressure is exerted for the evolution of drug-resistant strains. Based upon this new concept of disease pathogenesis, the best chance for preserving the immune system and for preventing the complications of AIDS may be to intervene to shut down viral replication with antiretroviral agents in combination. Viral load measurements, as a direct reflection of the degree of viral replication, have emerged as a new surrogate marker well suited to guiding decisions in clinical management.
Viral load measurements are excellent predictors of rapid progression to AIDS and death and correlate with these clinical outcomes better than CD4 T-cell count.67 Mellors and colleagues have reported from the Multi-center AIDS Cohort Study that individuals with viral load measurements greater than 104 copies/ml plasma within six months of seroconversion had a median survival of six years, compared to individuals without detectable virus (< 104 copies/ml plasma in this study) whose median survival was over 12 years.7 Those with viral load measured at greater than 105 copies/ml plasma were at greatest risk for death. While CD4 T-cell counts were also independent predictors of risk for disease progression and death, they were not as strongly predictive as viral load. Using the combination of viral load and CD4 T-cell count together was more predictive than either measurement alone. Similar analyses performed on stored sera from cohorts of injection drug users, hemophiliacs, and HIV-infected newborns (in whom CD4 T-cell counts are very poor surrogate markers) have confirmed that high HIV viral load is highly predictive of poor clinical outcomes in these groups as well. copies/ml plasma identifies a patient who, based upon our current understanding of pathogenesis, is likely to benefit from starting or changing antiretroviral therapy. A viral load in this range predicts disease progression independently of CD4 T-cell count. A patient with a relatively low viral load measurement (5000-10 000 copies/ml plasma) and a CD4 T-cell count less than 500/mm3 or HIV-related symptoms is also likely to benefit from antiretroviral agents.
After the initiation of therapy, a reduction of 0.5 log (3-fold) or more indicates effectiveness. Changes less than that in magnitude are not biologically meaningful. Though a reduction of 0.5 log documents significant antiretroviral effect, detectable virus levels of greater than 10 000 copies/ml plasma suggest ongoing viral replication. Though data from clinical trials to support this strategy are still forthcoming, many experts suggest that an undetectable viral load should be the goal of therapy if possible. Follow-up measurements every three to four months in conjunction with CD4 T-cell counts will provide useful information on the ongoing effectiveness of prescribed agents. A return in viral load to baseline measurements suggests a failing regimen and would provide a reason for instituting therapy change. Though some experts have proposed that two baseline viral measurements be obtained two to four weeks apart prior to starting antiretroviral therapy, the added expense of an extra test may be prohibitive in many settings. If a single measurement is obtained, certain clinical situations should be avoided. Transient increases in viral load measurements can occur following immune stimulation, such as with vaccinations or with new infections.'4 Also, the viral load is known to be several logs higher during and immediately following seroconversion, and a baseline set point may not be attained for six to twelve months. Consequently, "baseline" viral loads should not 
